Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls

医学 接种疫苗 免疫原性 反应性 不利影响 免疫系统 临床终点 免疫学 抗体 内科学 临床试验
作者
Felix Kartnig,Daniel Mrak,Elisabeth Simader,Selma Tobudic,Helga Radner,Péter Mandl,Lisa Göschl,Nikolaus Hommer,Margareta Mayer,Philipp Hofer,Thomas Hummel,Thomas Deimel,Irina Geßl,Antonia Puchner,Andreas Kerschbaumer,Renate Thalhammer,Alessandra Handisurya,Renate Kain,Stefan Winkler,Josef S Smolen
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:82 (2): 292-300 被引量:25
标识
DOI:10.1136/ard-2022-222682
摘要

Objectives A third COVID-19 vaccination is recommended for immunosuppressed patients. However, data on immunogenicity and safety of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMIDs) are sparse and therefore addressed within this clinical trial. Methods 60 immunosuppressed patients and 48 healthy controls (HCs) received a third vaccination with an mRNA vaccine. The primary endpoint was defined as the presence of antibody levels against the receptor-binding domain (RBD)>1500 BAU/mL in patients with IMIDs versus HCs. Further endpoints included differences in neutralising antibodies and cellular immune responses after the third vaccination. Reactogenicity was recorded for 7 days, and safety was evaluated until week 4. Results Rate of individuals with anti-RBD antibodies>1500 BAU/mL was not significantly different after the third vaccination between patients with IMIDs and HCs (91% vs 100% p=0.101). Anti-RBD and neutralising antibody levels were significantly lower in patients with IMIDs after the third vaccination than in HCs (p=0.002 and p=0.016, respectively). In contrast, fold increase in antibody levels between week 0 and 4 was higher in patients with IMIDs. Treatment with biological (b) disease-modifying anti-rheumatic drugs (DMARD) or combination of bDMARDs and conventional synthetic DMARDs was associated with reduced antibody levels. Enhanced cellular immune response to wild type and Omicron peptide stimulation was observed after the third vaccination. No serious adverse event was attributed to the third vaccination. Conclusion Our clinical trial data support the immunogenicity and safety of a third COVID-19 vaccination in patients with IMIDs. However, effects of DMARD therapy on immunogenicity should be considered. Trial registration number EudraCT No: 2021-002693-10.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
甜甜的粥完成签到 ,获得积分10
刚刚
刚刚
睡一觉算了完成签到,获得积分10
刚刚
度度完成签到,获得积分10
刚刚
Nancy发布了新的文献求助30
刚刚
1秒前
黑猫黑猫发布了新的文献求助10
1秒前
jinyue完成签到 ,获得积分10
1秒前
1秒前
111发布了新的文献求助10
1秒前
2秒前
天天快乐的应助被jzhou65采纳,获得10
2秒前
多情天荷完成签到,获得积分10
2秒前
3秒前
Hhhhh完成签到,获得积分10
3秒前
周星宇完成签到,获得积分10
4秒前
丘比特的应助被fortuna采纳,获得10
4秒前
HE完成签到,获得积分10
4秒前
4秒前
Akim的应助被cc采纳,获得10
4秒前
搜集达人的应助被tt采纳,获得10
5秒前
失眠的紫霜完成签到,获得积分10
5秒前
是一个小朋友完成签到,获得积分10
5秒前
5秒前
愉快的宛海完成签到,获得积分10
5秒前
糖豆完成签到,获得积分10
6秒前
up完成签到,获得积分10
6秒前
Orange的应助被song采纳,获得10
6秒前
7秒前
Lingdongmei完成签到,获得积分10
7秒前
7秒前
可爱的函函的应助被chen采纳,获得80
7秒前
JUAN发布了新的文献求助10
7秒前
打打的应助被王哈哈采纳,获得10
7秒前
Joshua发布了新的文献求助10
8秒前
圆圆完成签到 ,获得积分10
8秒前
8秒前
852的应助被wt采纳,获得10
8秒前
8秒前
lelouch完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160467
求助须知:如何正确求助?哪些是违规求助? 9555463
关于积分的说明 21728123
捐赠科研通 7750270
什么是DOI,文献DOI怎么找? 3427393
关于科研通互助平台的介绍 2552425
邀请新用户注册赠送积分活动 2471741